NeuroPace, Inc. (NPCE): Price and Financial Metrics
GET POWR RATINGS... FREE!
NPCE Price/Volume Stats
| Current price | $4.50 | 52-week high | $6.50 |
| Prev. close | $4.50 | 52-week low | $1.22 |
| Day low | $4.35 | Volume | 7,600 |
| Day high | $4.53 | Avg. volume | 25,606 |
| 50-day MA | $4.53 | Dividend yield | N/A |
| 200-day MA | $3.55 | Market Cap | 114.32M |
NPCE Stock Price Chart Interactive Chart >
NPCE Stock Summary
- NEUROPACE INC's market capitalization of $114,705,209 is ahead of only 22.94% of US-listed equities.
- NPCE's went public 2.09 years ago, making it older than merely 6.98% of listed US stocks we're tracking.
- The volatility of NEUROPACE INC's share price is greater than that of 87.15% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to NEUROPACE INC, a group of peers worth examining would be MASS, MMAT, BASE, LEDS, and MOMO.
- NPCE's SEC filings can be seen here. And to visit NEUROPACE INC's official web site, go to www.neuropace.com.
NPCE Valuation Summary
- In comparison to the median Healthcare stock, NPCE's price/sales ratio is 9.09% higher, now standing at 2.4.
- NPCE's EV/EBIT ratio has moved up 40.8 over the prior 25 months.
Below are key valuation metrics over time for NPCE.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| NPCE | 2023-05-23 | 2.4 | 4.2 | -2.5 | -4.6 |
| NPCE | 2023-05-22 | 2.4 | 4.3 | -2.6 | -4.7 |
| NPCE | 2023-05-19 | 2.4 | 4.2 | -2.5 | -4.6 |
| NPCE | 2023-05-18 | 2.2 | 3.9 | -2.3 | -4.5 |
| NPCE | 2023-05-17 | 2.2 | 4.0 | -2.4 | -4.5 |
| NPCE | 2023-05-16 | 2.2 | 3.9 | -2.4 | -4.5 |
NPCE Price Target
For more insight on analysts targets of NPCE, see our NPCE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $27.50 | Average Broker Recommendation | 1.3 (Strong Buy) |
NeuroPace, Inc. (NPCE) Company Bio
NeuroPace, Inc. operates as a medical device company in the United States. The company develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. Its RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Latest NPCE News From Around the Web
Below are the latest news stories about NEUROPACE INC that investors may wish to consider to help them evaluate NPCE as an investment opportunity.
Q1 2023 Neuropace Inc Earnings CallQ1 2023 Neuropace Inc Earnings Call |
NeuroPace Reports First Quarter 2023 Financial Results and Increases Full Year 2023 Revenue GuidanceFirst quarter 2023 revenue increased 27% year-over-year to $14.5 million Full-year revenue guidance updated on strength of first quarter performance. Now expected to be $52-$54 million, up from $50-$52 million MOUNTAIN VIEW, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the first quarter ended March 31, 2023. Recent Highlights |
NeuroPace to Report First Quarter 2023 Financial Results on May 4, 2023MOUNTAIN VIEW, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the first quarter of 2023 after market close on Thursday, May 4, 2023. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the confe |
Further Upside For NeuroPace, Inc. (NASDAQ:NPCE) Shares Could Introduce Price Risks After 39% BounceDespite an already strong run, NeuroPace, Inc. ( NASDAQ:NPCE ) shares have been powering on, with a gain of 39% in the... |
NeuroPace to Present at the 22nd Annual Needham Virtual Healthcare ConferenceMOUNTAIN VIEW, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will be participating in the upcoming 22nd Annual Needham Virtual Healthcare Conference. Management is scheduled to present on Monday, April 17th, 2023 at 7:15 a.m. Pacific Time / 10:15 a.m. Eastern Time. A live webcast of this event, as well as an archived recording, will be availa |
NPCE Price Returns
| 1-mo | -10.00% |
| 3-mo | -12.28% |
| 6-mo | 179.50% |
| 1-year | -27.77% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 202.01% |
| 2022 | -85.22% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...